Personalized Approach to Thyroid Disorders Virtual Program Accreditation Statement
Register for the ATA 2020 10-Webinar Summer Series as one convenient package or register for each webinar individually.REGISTER NOW
The Endocrine Society designates this American Thyroid Association activity for AMA PRA Category 1 Credit™ and ABIM MOC Points. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation. Please view the individual webinar listings for credit available per course.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
As an accredited provider of Continuing Medical Education (CME) by the Accreditation Council for Continuing Medical Education (ACCME), the Endocrine Society is also able to provide Maintenance of Certification (MOC) points through the ABIM MOC Assessment Recognition Program. As such, the Endocrine Society ensures that activities registered by the Society for ABIM MOC recognition meet the requirements for all MOC activities as defined by the American Board of Internal Medicine (ABIM). The Endocrine Society is responsible for submitting participant completion information to ACCME for the purpose of granting ABIM MOC credit.
The Endocrine Society is providing MOC credits for this ATA activity. As such, in order to earn and report MOC points to the American Board of Internal Medicine, you must provide your board-certification information in your Endocrine Society educational profile.
Links to evaluate and claim CME or MOC are available after purchasing and viewing each webinar online.
Upon completion of the two (2) webinars associated with this educational activity, learners will be able to:
- Understand how to personalize management of thyroid disease in pregnancy.
- Personalize the management of primary hypothyroidism of autoimmune origin and after thyroidectomy.
- Optimize the options for management of thyrotoxicosis
- Risk-adapt the management of papillary microcarcinomas and other low risk well-differentiated thyroid cancers
- Tailor the treatment of advanced thyroid cancer based on molecular features, pathologic characteristics, and a risk-adapted approach.
- Describe demographic factors that make clinicians evaluate pregnant patients for treatment of thyroid disorders.
- Explain the indications, risks, and benefits of treating pregnant patients with thyroid disease.
- Explain challenging scenarios in the treatment of patients with hypothyroidism after thyroidectomy and autoimmune hypothyroidism.
- Understand the utility of decision-support tools to help patients and physicians discuss different treatment modalities in the management of hyperthyroidism and thyroid cancer.
- Identify the specific scenarios in which molecular testing of tumors becomes informative and provides the basis for an individualized therapeutic strategy.
Faculty who have reported no relevant financial relationship(s) during the content development process for this activity are: Laura Boucai, MD, Anne R. Cappola, MD, ScM, Ramona Dadu, MD, Cari Meinhold Kitahara, PhD, Masha J. Livhits, MD, Sarah C. Oltmann, MD, Maria Papaleontiou, MD, Elizabeth N. Pearce, MD, Susan C. Pitt, MD, Reese W. Randle, MD, FACS, Jennifer E. Rosen, MD, FACS, Mabel M. Ryder, MD, Rebecca S. Sippel, MD, FACS, Martha A. Zeiger, MD, FACS, FACE
Faculty who have reported relevant financial relationship(s):
- Francesco S. Celi, MD, MHSc: Consultant: Acella Pharmaceuticals, IBSA Pharma Inc., Kashiv Biosciences Speaker honorarium: IBSA Pharma Inc.
- Patrick Ha, MD, FACS: Advisory Board: Loxo/Bayer Oncology; Primary Investigator (Educational
- funding): Stryker, Synthes, KLS Martin, Ethicon, Axogen
- Tim Korevaar, MD, PhD: Lectureship fees: Goodlife Healthcare, Berlin Chemie, Quidel
- Jennifer A. Sipos, MD: Advisory Board: Eli Lilly
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable. Endocrine Society and the American Thyroid Association staff associated with the development of content for this activity reported no relevant financial relationships.